A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects With Diabetic Peripheral Neuropathic Pain
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs ETX 018810 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Eliem Therapeutics
- 02 Aug 2022 According to an Eliem Therapeutics media release, based on results from this trial and NCT04778592 trial the company has decided to discontinue development of ETX-810.
- 25 Apr 2022 According to a Eliem Therapeutics media release, Primary endpoint ( To evaluate the efficacy of ETX 018810 on neuropathic pain via daily pain measurements in subjects with diabetic peripheral neuropathic pain (DPNP)) has not been met.
- 24 Mar 2022 Status changed from active, no longer recruiting to completed.